MN-DTN
31.3.2020 15:02:06 CEST | Business Wire | Press release
Weather is always a factor when considering the safety of lives and structures, but with the overwhelming response to the COVID-19 crisis and the volatility of spring weather these risks are amplified. Triage tents and other temporary outdoor structures are extremely vulnerable to weather events, as are other lifesaving operations. Hospitals may not be able to relocate patients during hazardous weather and first response efforts may be challenging.
That is why DTN, an independent source of insights, analysis and decision-support solutions, announced today that it is supporting hospitals, medical institutions, public health agencies, and first responders worldwide by offering its premier weather app service WeatherSentry at no cost during the COVID-19 pandemic.
“At DTN we are committed to providing our insights to support those who feed, fuel and protect our world,” said Mike Eilts, DTN senior vice president-weather. “Our healthcare workers and organizations are on the frontlines of protecting citizens worldwide and, in some cases, working in less-than-ideal structures. It is important that they have access to the best weather information available at their fingertips should the need arise, so they can quickly react and ensure the safety of their patients and themselves in the event of severe weather.”
Healthcare workers, hospitals, public health agencies and first responders globally can register for two free months of WeatherSentry. The subscription includes web and mobile app access to professional-grade alerting for mobile positions and fixed locations; real-time lightning display and alerts; severe weather storm tracks via radar; hourly and 15-day forecasts; and access to DTN meteorologists 24 hours a day, seven days a week.
“DTN has long been there, supporting our customers globally with unmatched insights during difficult situations, such as extreme weather events and customers working outdoors,” said Eilts. “We are proud to be providing WeatherSentry to support our world’s healthcare organizations and first responders when they need the information the most.”
Forecast timing and accuracy, as well as real-time alerts are crucial to lessening the impact to lives during dangerous weather situations. WeatherSentry users get access to precise, accurate, and reliable weather information delivered in a single screen, and updated as conditions change.
WeatherSentry is available for Android phone and tablet users at the Google Play store and for iOS devices on the App store once the free subscription has been authorized. To learn more and to sign up for the complimentary service, visit the DTN WeatherSentry for COVID-19 responders page.
About DTN
DTN delivers accurate, objective, real-time, and actionable insights to increase customers’ confidence and support business decisions. In a data-rich world, these actionable insights in weather and financial analytics make sense of the information, drive change in processes and help businesses prosper. DTN empowers agriculture, energy and transportation customers – those who work endlessly to feed, fuel and protect our world. We believe that when our customers are supported with the most reliable and innovative information to the Nth Degree, they prosper and we all win. DTN’s highly accurate and reliable solutions are backed by more than 140 patents. The company publishes Progressive Farmer magazine, the premier publication in agriculture, and is headquartered in Minneapolis, Minnesota.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
